Kinnate Biopharma
Presence
Kinnate Biopharma is a company listed under the stock ticker KNTE (US).
Executives
View the org chart displaying its 9 main executives
Most searched biographies at Kinnate Biopharma
- Laurie Smaldone, Director
- Richard Williams, Chief Medical Officer
- Barbara Warren, Vice President, People and Culture
Popular executive movements at Kinnate Biopharma
- Dean Mitchell, Chairman of the Board, has left the company (posted on April 5 2024).
- Nima Farzan, Chief Executive Officer and Director, has left the company (posted on April 5 2024).
- Melissa Epperly, Director, has left the company (posted on April 5 2024).
Click here to view some more movements at Kinnate Biopharma
Create your alert
to follow the executive moves at Kinnate Biopharma.
Biotechnology
Kinnate Biopharma has 2,286 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Kinnate Biopharma
- Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates | Kinnate Biopharma
- Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring | Kinnate Biopharma
- Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates | Kinnate Biopharma
- Press Releases | Kinnate Biopharma
- Press Releases | Kinnate Biopharma
- Publications / Presentations | Kinnate Biopharma
- Press Releases | Kinnate Biopharma
- Kinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference | Kinnate Biopharma
- Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences | Kinnate Biopharma
- Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022 | Kinnate Biopharma
- View more press releases Close
Social media about Kinnate Biopharma
- Kinnate Biopharma on Wikipedia, Google News & Yahoo Finance
- Kinnate Biopharma on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Laurie Smaldone 
Call Kinnate Biopharma at +1 415...
